In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound pharmacy of selling versions of its Wegovy and Ozempic medicines, which are widely prescribed for weight loss and have become franchise products for the drug company.
The decision, which was conveyed in a one-page filing in the court docket, comes after Novo Nordisk filed lawsuits last July against Brooksville Pharmaceuticals and three other compound pharmacies for allegedly violating laws in different states. The drug maker argued the compounders were selling versions of its medicines that were never approved by the U.S. Food and Drug Administration.
The compound pharmacy declined to comment, as did its attorney, Matthew Modafferi. However, he explained that U.S. District Court Judge William Jung left the door open for Novo Nordisk to file an amended lawsuit. This suggests the case may continue if drug maker takes such a step. A Novo Nordisk spokeswoman told us the company plans to file an amended lawsuit explaining why it believes the pharmacy violated Florida state law.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect